ES2192779T3 - Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico. - Google Patents

Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.

Info

Publication number
ES2192779T3
ES2192779T3 ES98934929T ES98934929T ES2192779T3 ES 2192779 T3 ES2192779 T3 ES 2192779T3 ES 98934929 T ES98934929 T ES 98934929T ES 98934929 T ES98934929 T ES 98934929T ES 2192779 T3 ES2192779 T3 ES 2192779T3
Authority
ES
Spain
Prior art keywords
modification
triazol
carboxamide
difluorbencil
antiepileptico
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98934929T
Other languages
English (en)
Spanish (es)
Inventor
Robert Portmann
Urs Christoph Hofmeier
Andreas Burkhard
Walter Scherrer
Martin Szelagiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2192779(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2192779T3 publication Critical patent/ES2192779T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES98934929T 1997-06-10 1998-06-08 Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico. Expired - Lifetime ES2192779T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10

Publications (1)

Publication Number Publication Date
ES2192779T3 true ES2192779T3 (es) 2003-10-16

Family

ID=4209650

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98934929T Expired - Lifetime ES2192779T3 (es) 1997-06-10 1998-06-08 Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.
ES98934930T Expired - Lifetime ES2197485T3 (es) 1997-06-10 1998-06-08 Modificacion cristalina de 1-(2,6-difluorobencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98934930T Expired - Lifetime ES2197485T3 (es) 1997-06-10 1998-06-08 Modificacion cristalina de 1-(2,6-difluorobencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.

Country Status (36)

Country Link
US (6) US6740669B1 (cg-RX-API-DMAC7.html)
EP (2) EP0994863B1 (cg-RX-API-DMAC7.html)
JP (2) JP3672575B2 (cg-RX-API-DMAC7.html)
KR (2) KR100425656B1 (cg-RX-API-DMAC7.html)
CN (3) CN1159300C (cg-RX-API-DMAC7.html)
AR (4) AR012946A1 (cg-RX-API-DMAC7.html)
AT (2) ATE237599T1 (cg-RX-API-DMAC7.html)
AU (2) AU725517B2 (cg-RX-API-DMAC7.html)
BR (2) BR9804947A (cg-RX-API-DMAC7.html)
CA (3) CA2256015C (cg-RX-API-DMAC7.html)
CO (2) CO4940452A1 (cg-RX-API-DMAC7.html)
CY (1) CY2007014I1 (cg-RX-API-DMAC7.html)
CZ (2) CZ292260B6 (cg-RX-API-DMAC7.html)
DE (3) DE69813560T2 (cg-RX-API-DMAC7.html)
DK (2) DK0994863T3 (cg-RX-API-DMAC7.html)
ES (2) ES2192779T3 (cg-RX-API-DMAC7.html)
FR (1) FR07C0037I2 (cg-RX-API-DMAC7.html)
HU (2) HU225153B1 (cg-RX-API-DMAC7.html)
ID (2) ID21014A (cg-RX-API-DMAC7.html)
IL (2) IL125732A (cg-RX-API-DMAC7.html)
LU (1) LU91345I2 (cg-RX-API-DMAC7.html)
MY (2) MY120156A (cg-RX-API-DMAC7.html)
NL (1) NL300284I2 (cg-RX-API-DMAC7.html)
NO (2) NO329315B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ331370A (cg-RX-API-DMAC7.html)
PE (2) PE79799A1 (cg-RX-API-DMAC7.html)
PL (2) PL191943B1 (cg-RX-API-DMAC7.html)
PT (1) PT994864E (cg-RX-API-DMAC7.html)
RU (2) RU2198167C2 (cg-RX-API-DMAC7.html)
SI (2) SI0994864T1 (cg-RX-API-DMAC7.html)
SK (2) SK283734B6 (cg-RX-API-DMAC7.html)
TR (2) TR199801631T1 (cg-RX-API-DMAC7.html)
TW (2) TW403740B (cg-RX-API-DMAC7.html)
UY (1) UY25844A1 (cg-RX-API-DMAC7.html)
WO (2) WO1998056772A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA984967B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
MXPA04011865A (es) * 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
NZ591725A (en) * 2008-10-13 2012-09-28 Cipla Ltd PROCESS FOR THE PREPARATION OF RUFINAMIDE which is also known as 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
EP2473051B1 (en) * 2009-09-04 2016-02-10 Tactical Therapeutics, Inc. Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
EP2727914A1 (en) 2010-04-30 2014-05-07 Laboratorios Lesvi, S.L. Polymorph of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-carboxamide
ITMI20110718A1 (it) 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
WO2014013511A2 (en) * 2012-07-20 2014-01-23 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
PH22568A (en) * 1985-04-18 1988-10-17 Ciba Geigy Ag Fluorinated benzyl triazoles and pharmaceutical compositions containing the same
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
JPH04506967A (ja) 1989-07-27 1992-12-03 ジー．ディー．サール　アンド　カンパニー 高血圧症治療用腎選択性生成物
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP2550456B2 (ja) 1990-11-06 1996-11-06 山之内製薬株式会社 縮合ピラジン誘導体
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
CN1072215C (zh) 1995-02-22 2001-10-03 赫彻斯特药品和化学品公司 无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
JP3537147B2 (ja) * 1996-07-11 2004-06-14 ノバルティス アクチエンゲゼルシャフト １―置換４―シアノ―１，２，３―トリアゾールの製造法
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
DE122007000051I2 (de) 2009-02-19
IL125733A0 (en) 1999-04-11
DE122007000051I1 (de) 2007-11-08
IL125733A (en) 2002-12-01
CN1298708C (zh) 2007-02-07
PL191943B1 (pl) 2006-07-31
EP0994863A1 (en) 2000-04-26
DE69811500T2 (de) 2004-04-01
NO329315B1 (no) 2010-09-27
HU226107B1 (en) 2008-04-28
HU225153B1 (en) 2006-07-28
JP3672575B2 (ja) 2005-07-20
AR061005A2 (es) 2008-07-30
TR199801631T1 (xx) 1999-06-21
BR9804947A (pt) 1999-08-24
CO4940452A1 (es) 2000-07-24
NO983666L (no) 1998-12-17
HK1028241A1 (en) 2001-02-09
CZ292260B6 (cs) 2003-08-13
CA2256013A1 (en) 1998-12-17
HUP0002113A2 (hu) 2001-02-28
SK109398A3 (en) 1998-12-02
HUP0002113A3 (en) 2002-09-30
US20040167186A1 (en) 2004-08-26
US20060116520A1 (en) 2006-06-01
UY25844A1 (es) 2001-08-27
IL125732A (en) 2002-12-01
ES2197485T3 (es) 2004-01-01
KR19990087835A (ko) 1999-12-27
CZ292481B6 (cs) 2003-09-17
US8076362B2 (en) 2011-12-13
US20030125568A1 (en) 2003-07-03
CN1217716A (zh) 1999-05-26
WO1998056772A1 (en) 1998-12-17
JP2000516259A (ja) 2000-12-05
PL192114B1 (pl) 2006-08-31
EP0994864A1 (en) 2000-04-26
KR19990087836A (ko) 1999-12-27
US20010037029A1 (en) 2001-11-01
CY2007014I2 (el) 2009-11-04
US20100310655A1 (en) 2010-12-09
PE80999A1 (es) 1999-09-06
HUP0000798A3 (en) 2000-10-30
TW526195B (en) 2003-04-01
FR07C0037I2 (cg-RX-API-DMAC7.html) 2008-05-16
SK283685B6 (sk) 2003-12-02
RU2198167C2 (ru) 2003-02-10
JP2000516258A (ja) 2000-12-05
PE79799A1 (es) 1999-09-03
SI0994863T1 (en) 2003-08-31
BR9804946A (pt) 1999-08-24
IL125732A0 (en) 1999-04-11
CZ253498A3 (cs) 1999-04-14
ATE237599T1 (de) 2003-05-15
AU725528B2 (en) 2000-10-12
AU8437198A (en) 1998-12-30
DE69811500D1 (de) 2003-03-27
AR061004A2 (es) 2008-07-30
ZA984967B (en) 1999-01-11
TR199801630T1 (xx) 1999-06-21
NO983666D0 (no) 1998-08-11
KR100425656B1 (ko) 2004-05-17
SI0994864T1 (en) 2003-10-31
CA2614926C (en) 2010-02-09
TW403740B (en) 2000-09-01
KR100409168B1 (ko) 2004-01-31
CN1159300C (zh) 2004-07-28
CA2614926A1 (en) 1998-12-17
ID27660A (id) 2001-04-19
CA2256013C (en) 2007-10-16
AU725517B2 (en) 2000-10-12
PL330798A1 (en) 1999-06-07
HUP0000798A2 (hu) 2000-10-30
NO329314B1 (no) 2010-09-27
FR07C0037I1 (cg-RX-API-DMAC7.html) 2007-08-17
DE69813560T2 (de) 2004-02-05
NZ331370A (en) 2000-08-25
EP0994863B1 (en) 2003-02-19
AR012946A1 (es) 2000-11-22
CZ253398A3 (cs) 1999-04-14
CO4940448A1 (es) 2000-07-24
CN1259127A (zh) 2000-07-05
US6740669B1 (en) 2004-05-25
MY120156A (en) 2005-09-30
MY125854A (en) 2006-08-30
PT994864E (pt) 2003-07-31
ID21014A (id) 1999-04-08
EP0994864B1 (en) 2003-04-16
JP3672574B2 (ja) 2005-07-20
DK0994864T3 (da) 2003-07-21
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
SK283734B6 (sk) 2003-12-02
WO1998056773A1 (en) 1998-12-17
LU91345I9 (cg-RX-API-DMAC7.html) 2018-12-31
NO983667L (no) 1998-12-17
LU91345I2 (fr) 2007-09-04
CN1132820C (zh) 2003-12-31
US7750028B2 (en) 2010-07-06
RU2194041C2 (ru) 2002-12-10
AU8437298A (en) 1998-12-30
CA2256015A1 (en) 1998-12-17
PL330764A1 (en) 1999-05-24
DE69813560D1 (de) 2003-05-22
NZ331371A (en) 2000-08-25
CA2256015C (en) 2008-06-03
SK109498A3 (en) 1998-12-02
US6455556B2 (en) 2002-09-24
HK1028242A1 (en) 2001-02-09
HK1028031A1 (en) 2001-02-02
NL300284I2 (nl) 2007-11-01
ZA984966B (en) 1999-01-11
ATE232852T1 (de) 2003-03-15
AR012945A1 (es) 2000-11-22
DK0994863T3 (da) 2003-05-26
CN1572789A (zh) 2005-02-02
CY2007014I1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
ES2192779T3 (es) Modificacion cristalina de 1-(2,6-difluorbencil)-1h-1,2,3-triazol-4-carboxamida y su uso como antiepileptico.
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
BR0200782A (pt) Compostos para o tratamento da isquemia
MX9804597A (es) Derivados de bencimidazol sustituidos por naftilo como anticoagulantes.
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
AR005940A1 (es) Composicion cosmetica de fijacion y brillo en aerosol, y procedimiento
ES2174039T3 (es) Utilizacion de al menos un peptido que contiene el tripeptido lys-dpro-arg para la preparacion de un medicamento para el tratamiento de la inflamacion.
BR9814299A (pt) Aminobiguanidas e o seu uso para desinfetarlentes de contato e preservar composiçõesfarmacêuticas
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
ES2132430T3 (es) Derivados de la quinolonilcarboxamidocefalosporina y composiciones farmaceuticas que los contienen.
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
AR008154A1 (es) Acido (s)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil- -3-oxo-1h-1,4-benzodiazepina-2-acetico, como hidrocloruro del mismo, unacomposicion farmaceutica que lo comprende, el uso del mismo y un procedimiento para su preparacion.
BR9902347A (pt) Azabiciclos como inibidores de rotomase
ATE211489T1 (de) Chitosan enthaltende zusammensetzung
DK0699030T3 (da) Mikrobicide midler
TR199902815T2 (xx) Anksiyete ve gerginlik tedavisinde 1-ar(alk) ilimidazolin-2-tek kullan�m�